Akari Therapeutics, Plc (AKTX)
NASDAQ: AKTX · Real-Time Price · USD
5.12
-0.60 (-10.49%)
Apr 29, 2026, 12:32 PM EDT - Market open

Akari Therapeutics, Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2016
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2016
Net Income
-17.3-19.79-10.01-17.75-17.42
Upgrade
Depreciation & Amortization
-0.01000
Upgrade
Asset Writedown & Restructuring Costs
5.18----
Upgrade
Stock-Based Compensation
2.892.251.150.740.31
Upgrade
Other Operating Activities
-0.94-1.56-6.71-5.320.24
Upgrade
Change in Accounts Payable
-15.22-0.94-0.88-0.24
Upgrade
Change in Other Net Operating Assets
0.591.320.071.7-1.74
Upgrade
Operating Cash Flow
-10.57-12.55-16.43-21.5-18.85
Upgrade
Cash Acquisitions
-0.38---
Upgrade
Investing Cash Flow
-0.38---
Upgrade
Short-Term Debt Issued
2.11---
Upgrade
Total Debt Issued
2.11---
Upgrade
Short-Term Debt Repaid
-1.05-1.86---
Upgrade
Total Debt Repaid
-1.05-1.86---
Upgrade
Net Debt Issued (Repaid)
1.05-0.86---
Upgrade
Issuance of Common Stock
10.7611.847.0225.2914.29
Upgrade
Other Financing Activities
1.37----
Upgrade
Financing Cash Flow
13.1710.997.0225.2914.29
Upgrade
Foreign Exchange Rate Adjustments
0-00.010.11-0.14
Upgrade
Net Cash Flow
2.6-1.19-9.413.89-4.69
Upgrade
Free Cash Flow
-10.57-12.55-16.43-21.5-18.85
Upgrade
Free Cash Flow Per Share
-12.56-42.04-134.29-275.54-351.28
Upgrade
Cash Interest Paid
0.10.14---
Upgrade
Levered Free Cash Flow
-10.223.91-16.74-6.04-11.31
Upgrade
Unlevered Free Cash Flow
-9.634.06-16.74-6.04-11.31
Upgrade
Change in Working Capital
-0.46.54-0.870.82-1.98
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.